*LUPER Clinical study. Final phase (Lurbinectedin + Pembrolizumab)* One of the effective treatments for the Extensive Stage Small cell lung carcinoma that is progressing despite platinum based chemotherapy. The expected Overall Response Rate (ORR) is 40-50% that is much higher than currently available chemotherapy +/- immunotherapy. *#medlung Talks🫁*